Biotech

Zymeworks has a 69 per cent upside, says Paradigm Capital

Clinical-stage biopharmaceutical company Zymeworks (Zymeworks Stock Quote, Chart TSX, NYSE:ZYME) has a new licensing agreement for its proprietary Zymelink antibody-drug conjugate (ADC) platform, an event which Paradigm Capital analyst Rahul Sarugaser says is further proof that Zymeworks’ platfor ...

Three Finalists Announced for the 2019 Bloom Burton Award

Three Finalists Announced for the 2019 Bloom Burton Award Award Recognizes the Year’s Most Significant Contributor to Canada’s Innovative Healthcare Industry TORONTO, May 6, 2019 – Bloom Burton & Co. is pleased to announce the three finalists for the 2019 Bloom Burton Award. Bestowed annually ...

Tetra Bio-Pharma is a leader in the cannabis biopharmaceutical space: Paradigm

A high need for safe and effective pain drugs in the wake of the opioid crisis shows the potential value in Tetra Bio-Pharma’s (Tetra Bio-Pharma Stock Quote, Chart TSXV:TBP) cannabinoid drug candidate, CAUMZ. That’s according to analyst Rahul Sarugaser of Paradigm Capital, who in a Thursday res ...

Zymeworks has an upside of 82 per cent, Paradigm Capital says

Paradigm Capital analyst Rahul Sarugaser says he’s spotted a consistent lag in the market’s appreciation of material developments concerning clinical-stage biopharmaceutical company Zymeworks (Zymeworks Stock Quote, Chart NYSE:ZYME), one which makes for a great buying opportunity. In an update ...

Tetra Bio-Pharma has an upside of 146%, Paradigm Capital says

A new collaboration to develop a cannabis-based treatment of brain cancer is a step in the right direction for Tetra Bio-Pharma (Tetra Bio-Pharma Stock Quote, Chart TSXV:TBP), according to Rahul Sarugaser, analyst for Paradigm Capital, who in a research note Thursday said TBP could become the next ...

DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions

DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis’ market-leading platform, bringing together the most relevant information to support… The post DrugPatentWatch Partners with Adis: Helping Drug C ...

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio Clementia’s late-stage drug candidate, palovarotene, has rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder and a path to approval in 2020 Acquisi ...

Cyclicals and Biotechs are Trading Above Their 200-Day Lines

Editor's Note: This article was originally published in John Murphy's Market Message on Thursday, January 31st at 12:34pm ET. Chart 4 shows the Consumer Discretionary SPDR (XLY) trading above its 200-day line in today's trading. That a positive sign for the economically-sensitive sector and th ...

The Science of Commercialization

November 8, 2018; Hamilton, Ontario, Canada; Triumvira is a company started by Dr. Jonathan Bramson, associate dean of research for the Faculty of Health Sciences, McMaster University, along with colleagues Chris Helsen and Danielle Hayes. Photo by Ron Scheffler for McMaster University. This arti ...

Q4 2018 Share Price Performance

Analysis: Stocks Get Hammered  In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 4Q-2018, and provides commentary on select stock movements and overall market trends. Inclusion Criteria Our analysis includes all Canadian ...